Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 02, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Encouraging Pre-NDA Meeting With the FDA for Firdapse(TM) as a Treatment for Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...
January 12, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Provides an Update of 2015 Goals for Its Product Portfolio

Pre-NDA Meeting with the FDA Firdapse NDA Submission Developing Regulatory Strategy for Firdapse for Congenital Myasthenic Syndrome Hosting 1x1 Meetings in San Francisco January...
January 05, 2015 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer

CORAL GABLES, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and...
December 16, 2014 15:45 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founder and Director

CORAL GABLES, Fla., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and...
December 01, 2014 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference

CORAL GABLES, Fla., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and...
November 24, 2014 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115

CORAL GABLES, Fla., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and...
November 14, 2014 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Third Quarter 2014 Financial Results

CORAL GABLES, Fla., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and...
November 04, 2014 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Proposed Settlement of Pending Securities Class Action Lawsuit

CORAL GABLES, Fla., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals or the Company), a biopharmaceutical company focused on developing...
October 28, 2014 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Appoints David J. Caponera as Vice President Patient Advocacy and Reimbursement

CORAL GABLES, Fla., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...
October 27, 2014 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present Firdapse Phase 3 Trial Results at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine

CORAL GABLES, Fla., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and...